Drugs / TIL therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06783270 | Dec 2024 → Jan 2027 expected | metastatic melanoma | Inge Marie Svane | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIL-therapy | “This is a well known and tried treatment regimen, often called TIL-therapy or TIL-ACT.” NCT06783270 ↗ |
| Known as | TIL-ACT | “This is a well known and tried treatment regimen, often called TIL-therapy or TIL-ACT.” NCT06783270 ↗ |
| Action | Inhibit | “to silence the expression of PD-1 on the surface of the infused cells” NCT06783270 ↗ |
| Modality | Cell therapy | “tumor infiltrating lymphocytes (TILs) in combination with lymphodepleting chemotherapy” NCT06783270 ↗ |
| Route | Intravenous | “This is given as an intravenous infusion” NCT06783270 ↗ |